Holen Sie sich die Stockscreener-App
8.5981
0.36%
0.1981
Schlusskurs vom Vortag:
$8.40
Offen:
$8.4
24-Stunden-Volumen:
412.48K
Relative Volume:
0.40
Marktkapitalisierung:
$5.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0323
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+53.27%
1M Leistung:
+124.20%
6M Leistung:
-5.39%
1J Leistung:
-65.71%
1-Tages-Spanne:
$7.44
$9.40
1-Wochen-Bereich:
$6.20
$16.73
52-Wochen-Spanne:
$2.66
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.55 | 5.85M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.13 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.55 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.73 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.62 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.50 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
How Is The Market Feeling About TransCode Therapeutics? - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: TransCode Therapeutics +133.97%, Diginex +27.49% among top gainers during mid day trading - Business Upturn
Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register
Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register
Stock market today: Sentage Holdings +70.79%, Planet Image International +64.29% among top gainers in early trading - Business Upturn
TransCode Therapeutics Shares Are Surging Today: What's Going On? - Benzinga
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
Clinical Trials News Live Feed - StockTitan
Transcode Therapeutics doses first patient in third cohort of Phase 1trial - TipRanks
TransCode's TTX-MC138 Cancer Trial Advances: First Patient Dosed in Cohort 3 with Doubled Dose - StockTitan
Transcode Therapeutics stock hits 52-week low at $3.20 - Investing.com India
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - PR Newswire
TransCode Therapeutics Secures Nasdaq Listing Status After Meeting Critical Requirements - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in TransCode Therapeutics Inc - GuruFocus.com
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update - Defense World
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
HC Wainwright Has Optimistic Outlook of RNAZ FY2024 Earnings - Defense World
Analysts Issue Forecasts for RNAZ Q1 Earnings - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
H.C. Wainwright raises TransCode Therapeutics target following SRC go-ahead for Cohort 3 - Investing.com
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - StreetInsider.com
TransCode advances to third patient group in cancer trial - Investing.com India
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial - TipRanks
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Transcode Therapeutics stock hits 52-week low at $6.89 By Investing.com - Investing.com Canada
TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 - MSN
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
TransCode Therapeutics Raises $8M in Private Placement - TipRanks
Why TransCode Therapeutics (RNAZ) Stock Is Diving - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - The Manila Times
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News - StockTitan
TransCode Therapeutics announces $8M private offering - MSN
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement - Yahoo Finance
TransCode secures $8 million in private placement - Investing.com India
TransCode secures $8 million in private placement By Investing.com - Investing.com Australia
TransCode Therapeutics, Inc. Announces $8 Million Private Placement - The Manila Times
TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan
TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding - Marketscreener.com
Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.41%
5.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):